Manufacturing and sales of Dong-A ST's SGLT-2 inhibitor-type diabetes treatment Dapapro are expected to be suspended by early next month. According to the pharmaceutical industry on the 20th, the Seoul Central District Court recently cited AstraZeneca's request for an injunction to prohibit infringement of patent rights filed against Dong-A ST. As a result, Dong-A ST will not be able to manufacture and sell Dapapro until the 7th of next month, when Forxiga's patent expires.

Dapapro is a follow-on drug to Forxiga. Among the SGLT-2 inhibitors of Dapagliflozin, the original diabetes treatment, it is currently the only one listed as reimbursement, except Forxiga. In November of last year, Dong-A ST succeed